Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors
Fading2 outlets reported this in 4 reports over 2 days - a further 2 reports reprinted copy already published elsewhere
original reportingcopies
Sat, 29 August 2026peak 3 reports on Sat, 29 August 2026Thu, 3 September 2026
What it is about
Bristol Myers SquibbMoneyball SuperscoreAstrazenecaNvidiaNetflixDaniela HathornDonald TrumpPascal SoriotAstrazeneca Bristol Myers SquibbEnergy StocksReutersPfizerYahooShellOil Drop Lifts HousebuildersIranLondon, London, City Of, United KingdomSaudi Arabia
Who published it, and when
original reportcopyfirst to report
fool.com
yahoo.com
aol.com
financial-news.co.uk
29 Aug, 14:15over 5 days3 Sept, 16:18
How it spread - 2 original reports, 2 reprints
Sat, 29 August 2026
1 report- yahoo.com14:35first to report
Bristol Myers Squibb is facing down a major patent cliff, which is a problem and a huge motivating force.
2 reprints
- fool.com29 Aug, 14:15their copy
- aol.com29 Aug, 14:35their copy
Thu, 3 September 2026
1 report- financial-news.co.uk16:18
A report of an AstraZeneca Bristol Myers Squibb merger rattled London’s benchmark on Monday, wiping more than £17 billion off AstraZeneca’s market value and capping the FTSE 100’s advance even as European peers surged on easing geopolitical tensions. AstraZeneca fell around 5%, trimming significant points from the index, which traded flat by mid-morning. Brent crude